Future Issues: The Impact of the Affordable Care Act

Monday, November 19, 2012

by Carolyn Steigleman

With the President's reelection and the Supreme Court's ruling last June, it is clear that the Affordable Care Act will soon come to fruition. Stakeholders in U.S. healthcare delivery gathered on Saint Joseph's campus Friday, Nov. 16, to discuss its implementation during a conference hosted by the Department of Pharmaceutical and Healthcare Marketing: The Impact of the Affordable Care Act.

Bill Trombetta, J.D., professor of pharmaceutical and healthcare marketing, opened the conference and explained the challenge ahead. 

"The Affordable Care Act will introduce a tension into the healthcare delivery system," explained Trombetta. "Will the new regulations be a force for good: lower costs, improved outcomes and enhanced patient experience? Or, will it be a force for evil: a concentration resulting in a countervailing power of mega provider groups that can thumb their noses at healthcare insurers raising prices?"

With so much uncertainty, stakeholders in the U.S. healthcare system benefited from experts’ perspectives who discussed the Act’s potential impact on the industry and the nation.

The conference began with an overview of the current healthcare system and offered an explanation for how it has evolved over the years. This was followed by perspectives shared from many branches of the healthcare delivery system: insurance, pharmaceutical, physicians, nursing, government, and technology.

Featured speakers during the Future Issues 2012 Conference: The Impact of the Affordable Care Act included:

  • Dennis Cotter, president of the Medical Technology & Practice Patterns Institute
  • John Manion, consultant for Armstrong, Doyle and Carroll
  • Tony Chen, director of Evidence Pricing & Access at Heron Evidence Development, LLC. 
  • Tony Zook, executive vice president of AstraZeneca’s Global Commercial
  • James Dwyer, executive vice president for Physicians Services at Virtua Health  
  • Michael Grosso, senior medical director and global medical lead for the HOKUSAI-VTE trial at Daiichi-Sankyo Inc. 
  • Harry Morris, DO, professor and chair of the Department of Family Medicine at PCOM 
  • Karen Oxley - Rear Admiral Flaherty (retired) former Deputy Surgeon General of Navy Medicine at the Bureau of Medicine and Surgery.

Expand this section